questionsmedicales.fr
Hémopathies et maladies lymphatiques
Hémopathies
Tumeurs hématologiques
Tumeurs de la moelle osseuse
Tumeurs de la moelle osseuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs de la moelle osseuse : Questions médicales les plus fréquentes",
"headline": "Tumeurs de la moelle osseuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs de la moelle osseuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-14",
"dateModified": "2025-04-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs de la moelle osseuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs hématologiques",
"url": "https://questionsmedicales.fr/mesh/D019337",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs hématologiques",
"code": {
"@type": "MedicalCode",
"code": "D019337",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.400"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Polyglobulie primitive essentielle",
"alternateName": "Polycythemia Vera",
"url": "https://questionsmedicales.fr/mesh/D011087",
"about": {
"@type": "MedicalCondition",
"name": "Polyglobulie primitive essentielle",
"code": {
"@type": "MedicalCode",
"code": "D011087",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C15.378.400.200.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de la moelle osseuse",
"alternateName": "Bone Marrow Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D019046",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sa A Wang",
"url": "https://questionsmedicales.fr/author/Sa%20A%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, US."
}
},
{
"@type": "Person",
"name": "Adam Bagg",
"url": "https://questionsmedicales.fr/author/Adam%20Bagg",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, US."
}
},
{
"@type": "Person",
"name": "Robert P Hasserjian",
"url": "https://questionsmedicales.fr/author/Robert%20P%20Hasserjian",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Massachusetts General Hospital, Boston, MA, US."
}
},
{
"@type": "Person",
"name": "Eric D Hsi",
"url": "https://questionsmedicales.fr/author/Eric%20D%20Hsi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, US."
}
},
{
"@type": "Person",
"name": "Kathryn Foucar",
"url": "https://questionsmedicales.fr/author/Kathryn%20Foucar",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, University of New Mexico, Albuquerque, NM, US."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Feasibility of High-Cellular-Resolution Full-Field, Artificial-Intelligence-Assisted, Real-Time Optical Coherence Tomography in the Evaluation of Vitiligo: A Prospective Longitudinal Follow-Up Study.",
"datePublished": "2024-02-19",
"url": "https://questionsmedicales.fr/article/38391682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/bioengineering11020196"
}
},
{
"@type": "ScholarlyArticle",
"name": "HIV-1 Reverse Transcriptase Expression in HPV16-Infected Epidermoid Carcinoma Cells Alters E6 Expression and Cellular Metabolism, and Induces a Hybrid Epithelial/Mesenchymal Cell Phenotype.",
"datePublished": "2024-01-26",
"url": "https://questionsmedicales.fr/article/38399969",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v16020193"
}
},
{
"@type": "ScholarlyArticle",
"name": "SARS-CoV-2 viral genes Nsp6, Nsp8, and M compromise cellular ATP levels to impair survival and function of human pluripotent stem cell-derived cardiomyocytes.",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37705046",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13287-023-03485-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Veillonella parvula promotes the proliferation of lung adenocarcinoma through the nucleotide oligomerization domain 2/cellular communication network factor 4/nuclear factor kappa B pathway.",
"datePublished": "2023-07-14",
"url": "https://questionsmedicales.fr/article/37452162",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12672-023-00748-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.",
"datePublished": "2023-06-16",
"url": "https://questionsmedicales.fr/article/37331161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ebiom.2023.104661"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Hémopathies et maladies lymphatiques",
"item": "https://questionsmedicales.fr/mesh/D006425"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hémopathies",
"item": "https://questionsmedicales.fr/mesh/D006402"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs hématologiques",
"item": "https://questionsmedicales.fr/mesh/D019337"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs de la moelle osseuse",
"item": "https://questionsmedicales.fr/mesh/D019046"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs de la moelle osseuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs de la moelle osseuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs de la moelle osseuse",
"description": "Comment diagnostiquer une tumeur de la moelle osseuse ?\nQuels tests sont utilisés pour confirmer une tumeur ?\nQuels marqueurs tumoraux sont recherchés ?\nQuelle est l'importance de l'analyse cytogénétique ?\nLes tests génétiques sont-ils utiles ?",
"url": "https://questionsmedicales.fr/mesh/D019046?mesh_terms=Cellular+Reprogramming&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs de la moelle osseuse",
"description": "Quels sont les symptômes courants des tumeurs de la moelle osseuse ?\nComment la moelle osseuse affecte-t-elle la santé globale ?\nLes symptômes varient-ils selon le type de tumeur ?\nY a-t-il des signes d'alerte précoce ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D019046?mesh_terms=Cellular+Reprogramming&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs de la moelle osseuse",
"description": "Peut-on prévenir les tumeurs de la moelle osseuse ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?\nLes antécédents familiaux influencent-ils le risque ?\nY a-t-il des vaccins pour prévenir ces tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D019046?mesh_terms=Cellular+Reprogramming&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs de la moelle osseuse",
"description": "Quels traitements sont disponibles pour ces tumeurs ?\nLa radiothérapie est-elle efficace ?\nQu'est-ce que la thérapie ciblée ?\nQuand la greffe de moelle osseuse est-elle recommandée ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D019046?mesh_terms=Cellular+Reprogramming&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs de la moelle osseuse",
"description": "Quelles complications peuvent survenir ?\nComment les infections sont-elles liées aux tumeurs ?\nLes tumeurs de la moelle osseuse peuvent-elles récidiver ?\nQuelles sont les conséquences d'une anémie sévère ?\nLes traitements eux-mêmes peuvent-ils causer des complications ?",
"url": "https://questionsmedicales.fr/mesh/D019046?mesh_terms=Cellular+Reprogramming&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs de la moelle osseuse",
"description": "Quels sont les principaux facteurs de risque ?\nLes maladies génétiques augmentent-elles le risque ?\nLe sexe influence-t-il le risque de tumeurs ?\nL'obésité est-elle un facteur de risque ?\nLes infections virales peuvent-elles jouer un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D019046?mesh_terms=Cellular+Reprogramming&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur de la moelle osseuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par biopsie de moelle osseuse et analyses sanguines."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une tumeur ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme l'IRM et la TDM sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont recherchés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le B2-microglobuline et les chaînes légères d'immunoglobulines sont analysés."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'analyse cytogénétique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle aide à identifier des anomalies chromosomiques spécifiques aux tumeurs."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations spécifiques liées aux tumeurs."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des tumeurs de la moelle osseuse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, douleurs osseuses, infections fréquentes et saignements anormaux."
}
},
{
"@type": "Question",
"name": "Comment la moelle osseuse affecte-t-elle la santé globale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner une anémie, des infections et des problèmes de coagulation."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de tumeur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque type de tumeur peut présenter des symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte précoce ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inexpliqués et des ecchymoses peuvent être des signes d'alerte."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être similaires à ceux d'autres maladies hématologiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs de la moelle osseuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain aide."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques peut augmenter le risque de tumeurs."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers, y compris ceux de la moelle."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers hématologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ces tumeurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les tumeurs de la moelle."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour ces tumeurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent chimiothérapie, radiothérapie et greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la taille des tumeurs et soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la thérapie ciblée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui cible des anomalies spécifiques des cellules tumorales."
}
},
{
"@type": "Question",
"name": "Quand la greffe de moelle osseuse est-elle recommandée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent recommandée pour les cas avancés ou réfractaires aux traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, fatigue et immunosuppression."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, anémie sévère et défaillance organique."
}
},
{
"@type": "Question",
"name": "Comment les infections sont-elles liées aux tumeurs ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tumeurs peuvent affaiblir le système immunitaire, rendant les infections plus probables."
}
},
{
"@type": "Question",
"name": "Les tumeurs de la moelle osseuse peuvent-elles récidiver ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque de récidive après traitement, nécessitant un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une anémie sévère ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une anémie sévère peut entraîner une fatigue extrême et des complications cardiaques."
}
},
{
"@type": "Question",
"name": "Les traitements eux-mêmes peuvent-ils causer des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements comme la chimiothérapie peuvent entraîner des effets secondaires graves."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, l'exposition à des radiations et des produits chimiques."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques comme le syndrome de Down augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de tumeurs ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines tumeurs de la moelle osseuse sont plus fréquentes chez les hommes."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à un risque accru de plusieurs types de cancers."
}
},
{
"@type": "Question",
"name": "Les infections virales peuvent-elles jouer un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le VIH, peuvent augmenter le risque de tumeurs."
}
}
]
}
]
}
Vitiligo, a psychologically distressing pigmentary disorder characterized by white depigmented patches due to melanocyte loss, necessitates non-invasive tools for early detection and treatment respons...
The high incidence of epithelial malignancies in HIV-1 infected individuals is associated with co-infection with oncogenic viruses, such as high-risk human papillomaviruses (HR HPVs), mostly HPV16. Th...
Cardiovascular complications significantly augment the overall COVID-19 mortality, largely due to the susceptibility of human cardiomyocytes (CMs) to SARS-CoV-2 virus. SARS-CoV-2 virus encodes 27 gene...
CMs were derived from human pluripotent stem cells (hPSCs), including human embryonic stem cells and induced pluripotent stem cells, using 2D and 3D differentiation methods. We overexpressed Nsp6, M, ...
Nsp6, Nsp8, and M globally perturb the transcriptome and proteome of hPSC-CMs. SARS-CoV-2 infection and the overexpression of Nsp6, Nsp8, or M coherently upregulated genes associated with apoptosis an...
Overall, our findings uncover the extensive damaging effects of Nsp6, Nsp8, and M on hPSC-CMs, underlining the crucial role of ATP homeostasis in CM death and functional abnormalities induced by these...
Enrichment of Veillonella parvula in the lung microbiota is strongly associated with non-small cell lung cancer (NSCLC) and induces the progression of lung adenocarcinoma in vivo, but its actual role ...
We investigated long-term durability of humoral and cellular immune responses to third dose of BNT162b2 in people with HIV (PWH) and controls....
In 378 PWH with undetectable viral replication and 224 matched controls vaccinated with three doses of BNT162b2, we measured IgG-antibodies against the receptor binding domain of SARS-CoV-2 spike prot...
Before the third dose the concentration of SARS-CoV-2 antibodies was lower in PWH than in controls (unadjusted geometric mean ratio (GMR): 0.68 (95% CI: 0.54-0.86, p = 0.002). We observed no differenc...
We found no differences in antibody concentrations or cellular response between PWH and controls up to eleven months after third dose of BNT162b2. Our findings indicate that PWH with undetectable vira...
This work was funded by the Novo Nordisk Foundation (NFF205A0063505, NNF20SA0064201), the Carlsberg Foundation (CF20-476 0045), the Svend Andersen Research Foundation (SARF2021), and Bio- and Genome B...
A series of 2-phenylamino-3-acyl-1,4-naphtoquinones were evaluated regarding their in vitro antiproliferative activities using DU-145, MCF-7 and T24 cancer cells. Such activities were discussed in ter...
Cellular pharmacodynamic assays are crucial aspects of lead optimization programs in drug discovery. These assays are sometimes difficult to develop, oftentimes distal from the target and frequently l...
Individuals with weaker neutralizing responses show reduced protection with SARS-CoV-2 variants. Booster vaccines are recommended for vaccinated individuals, but the uptake is low. We present the feas...
SARS-CoV-2 point-of-care antibody tests are valuable and easy-to-access tools to inform inadequate humoral immunity and to support informed decision-making regarding the current and future booster vac...
Histology has not been accepted as a valid predictor of the biological behavior of extra-meningeal solitary fibrous tumors (SFTs). Based on the lack of a histologic grading system, a risk stratificati...
A series of five BODIPY derivatives with triarylamine (TPA) moieties on their 3-, 5-, or 8-positions were reported, which showed wide-range fluorescence emissions across red and near infrared regions ...